Notification

🚨 Trading Holiday 🚨

The NSE and BSE will remain closed for trading and settlement on Monday, April 14, 2025, on account of Dr. B. R. Ambedkar Jayanti.

Open a Free Demat Account

Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.

Trade Now, Pay Later with up to 4x

Never miss a good trading opportunity due to low funds with our MTF feature.

Track Market Movers Instantly

Stay updated with real-time data. Get insights at your fingertips.

NSE BSE

Trade Nowopens in a new tab

Mold-tek Technologies Ltd Share Price

₹ 154.74 4.36 (2.89%)

Apr 15 2025 03:30 PM Infrastructure Developers & Operators NSE: MOLDTECH

Mold-tek Technologies Ltd Share Price Update

As of the latest trading session, Mold-tek Technologies Ltd share price is currently at 154.74, which is up by 4.36 from its previous closing. Today, the stock has fluctuated between 151.60 and 155.45. Over the past year, Mold-tek Technologies Ltd has achieved a return of -33.82 %. In the last month alone, the return has been 28.07 %. Read More...

Mold-tek Technologies Ltd Performance

Day Range

Low151.60 High155.45

154.74

52 Week Range

Low 109.95 High 294.05

154.74

Mold-tek Technologies Ltd Share Price

17625

526263

MOLDTECH

Compare to down-arrow

View

Display

Studies

No Data Available

Open Price

154.90 Prev. Close

150.38 Volume (Shares)

55040.00

Total traded value

85.16 Upper Circuit

180.45 Lower Circuit

120.30

Note: The current prices & values are delayed, Loginopens in a new tab to your account for live updates.

Mold-tek Technologies Ltd Fundamentals

(Standalone)

Market Cap (Cr)	439.32
PE Ratio (TTM)	21.53
Book Value / Share	44.11
Beta	1.21

ROE	25.02%
EPS (TTM)	6.98
Dividend Yield	1.32%
Net Profit Qtr (Cr)	0.47

Mold-tek Technologies Ltd Financials

Key Results
Key Ratios
Balance sheet
Cash Flow
Competition

Revenue

Net income

Particulars	DEC 2024 (Values in Cr)
Revenue	29.57
Operating Expense	28.61
Net Profit	0.47
Net Profit Margin (%)	1.58
Earnings Per Share (EPS)	0.16
EBITDA	2.42
Effective Tax Rate (%)	26.56

Particulars	SEP 2024 (Values in Cr)
Revenue	39.59
Operating Expense	29.25
Net Profit	7.94
Net Profit Margin (%)	20.05
Earnings Per Share (EPS)	2.78
EBITDA	12.69
Effective Tax Rate (%)	26.13

Particulars	JUN 2024 (Values in Cr)
Revenue	35.00
Operating Expense	29.48
Net Profit	5.10
Net Profit Margin (%)	14.57
Earnings Per Share (EPS)	1.78
EBITDA	8.54
Effective Tax Rate (%)	23.53

Particulars	MAR 2024 (Values in Cr)
Revenue	39.09
Operating Expense	31.40
Net Profit	6.43
Net Profit Margin (%)	16.44
Earnings Per Share (EPS)	2.26
EBITDA	10.18
Effective Tax Rate (%)	22.62

Particulars	DEC 2023 (Values in Cr)
Revenue	37.53
Operating Expense	28.52
Net Profit	6.95
Net Profit Margin (%)	18.51
Earnings Per Share (EPS)	2.45
EBITDA	11.29
Effective Tax Rate (%)	25.45

Particulars	MAR 2024 (Values in Cr)
Revenue	146.17
Operating Expense	111.70
Net Profit	27.67
Net Profit Margin (%)	18.93
Earnings Per Share (EPS)	9.75
EBITDA	44.19
Effective Tax Rate (%)	25.06

Particulars	MAR 2023 (Values in Cr)
Revenue	133.26
Operating Expense	96.57
Net Profit	29.08
Net Profit Margin (%)	21.82
Earnings Per Share (EPS)	10.29
EBITDA	43.94
Effective Tax Rate (%)	24.70

Particulars	MAR 2022 (Values in Cr)
Revenue	90.29
Operating Expense	75.33
Net Profit	13.17
Net Profit Margin (%)	14.58
Earnings Per Share (EPS)	4.66
EBITDA	22.53
Effective Tax Rate (%)	26.05

Particulars	MAR 2021 (Values in Cr)
Revenue	76.02
Operating Expense	67.16
Net Profit	9.86
Net Profit Margin (%)	12.97
Earnings Per Share (EPS)	3.51
EBITDA	19.18
Effective Tax Rate (%)	29.49

Particulars	MAR 2020 (Values in Cr)
Revenue	90.85
Operating Expense	77.87
Net Profit	10.45
Net Profit Margin (%)	11.50
Earnings Per Share (EPS)	3.74
EBITDA	19.68
Effective Tax Rate (%)	22.66

Particulars	MAR 2024 (Values in Cr)
Book Value / Share	42.43
ROE %	24.71
ROCE %	31.39
Total Debt to Total Equity	0.08
EBITDA Margin	27.68

Particulars	MAR 2023 (Values in Cr)
Book Value / Share	36.74
ROE %	33.20
ROCE %	41.68
Total Debt to Total Equity	0.08
EBITDA Margin	30.15

Particulars	MAR 2022 (Values in Cr)
Book Value / Share	25.70
ROE %	19.88
ROCE %	25.50
Total Debt to Total Equity	0.08
EBITDA Margin	23.24

Particulars	MAR 2021 (Values in Cr)
Book Value / Share	21.83
ROE %	17.76
ROCE %	24.20
Total Debt to Total Equity	0.08
EBITDA Margin	23.75

Particulars	MAR 2020 (Values in Cr)
Book Value / Share	18.39
ROE %	21.06
ROCE %	27.27
Total Debt to Total Equity	0.08
EBITDA Margin	20.40

Particulars	MAR 2024 (Values in Cr)
Book Value / Share	41.66
ROE %	25.02
ROCE %	31.76
Total Debt to Total Equity	0.08
EBITDA Margin	30.29

Particulars	MAR 2023 (Values in Cr)
Book Value / Share	36.03
ROE %	33.67
ROCE %	42.26
Total Debt to Total Equity	0.08
EBITDA Margin	33.04

Particulars	MAR 2022 (Values in Cr)
Book Value / Share	25.12
ROE %	20.14
ROCE %	25.79
Total Debt to Total Equity	0.08
EBITDA Margin	25.09

Particulars	MAR 2021 (Values in Cr)
Book Value / Share	21.33
ROE %	17.94
ROCE %	24.48
Total Debt to Total Equity	0.09
EBITDA Margin	25.61

Particulars	MAR 2020 (Values in Cr)
Book Value / Share	17.92
ROE %	20.93
ROCE %	27.22
Total Debt to Total Equity	0.08
EBITDA Margin	22.20

Particulars	MAR 2024 (Values in Cr)
Cash & Short Term Investments	49.28
Total Assets	145.69
Total Liabilities	145.69
Total Equity	121.65
Share Outstanding	28391062
Price to Book Ratio	4.36
Return on Assets (%)	19.11
Return on Capital (%)	22.89

Particulars	MAR 2023 (Values in Cr)
Cash & Short Term Investments	31.88
Total Assets	129.32
Total Liabilities	129.32
Total Equity	103.77
Share Outstanding	28242563
Price to Book Ratio	6.76
Return on Assets (%)	22.63
Return on Capital (%)	28.2

Particulars	MAR 2022 (Values in Cr)
Cash & Short Term Investments	12.66
Total Assets	90.43
Total Liabilities	90.43
Total Equity	72.57
Share Outstanding	28242563
Price to Book Ratio	3.22
Return on Assets (%)	14.70
Return on Capital (%)	18.32

Particulars	MAR 2021 (Values in Cr)
Cash & Short Term Investments	12.74
Total Assets	76.30
Total Liabilities	76.30
Total Equity	61.21
Share Outstanding	28041158
Price to Book Ratio	1.91
Return on Assets (%)	13.11
Return on Capital (%)	16.34

Particulars	MAR 2020 (Values in Cr)
Cash & Short Term Investments	4.97
Total Assets	67.88
Total Liabilities	67.88
Total Equity	51.40
Share Outstanding	27954278
Price to Book Ratio	1.95
Return on Assets (%)	15.83
Return on Capital (%)	19.81

Particulars	MAR 2024 (Values in Cr)
Cash & Short Term Investments	27.92
Total Assets	143.49
Total Liabilities	143.49
Total Equity	119.44
Share Outstanding	28391062
Price to Book Ratio	4.36
Return on Assets (%)	19.28
Return on Capital (%)	23.16

Particulars	MAR 2023 (Values in Cr)
Cash & Short Term Investments	29.02
Total Assets	126.66
Total Liabilities	126.66
Total Equity	101.76
Share Outstanding	28242563
Price to Book Ratio	6.76
Return on Assets (%)	22.95
Return on Capital (%)	28.57

Particulars	MAR 2022 (Values in Cr)
Cash & Short Term Investments	7.75
Total Assets	88.80
Total Liabilities	88.80
Total Equity	70.95
Share Outstanding	28242563
Price to Book Ratio	3.22
Return on Assets (%)	14.83
Return on Capital (%)	18.56

Particulars	MAR 2021 (Values in Cr)
Cash & Short Term Investments	10.08
Total Assets	74.89
Total Liabilities	74.89
Total Equity	59.81
Share Outstanding	28041158
Price to Book Ratio	1.91
Return on Assets (%)	13.15
Return on Capital (%)	16.48

Particulars	MAR 2020 (Values in Cr)
Cash & Short Term Investments	0.64
Total Assets	66.58
Total Liabilities	66.58
Total Equity	50.10
Share Outstanding	27954278
Price to Book Ratio	1.95
Return on Assets (%)	15.68
Return on Capital (%)	19.73

Particulars	MAR 2024 (Values in Cr)
Net Income	37.09
Cash from Operations	42.02
Cash from Investing	-4.52
Cash from Financing	-10.60
Net change in Cash	17.38
Free Cash Flow	46.24

Particulars	MAR 2023 (Values in Cr)
Net Income	38.82
Cash from Operations	42.86
Cash from Investing	-11.35
Cash from Financing	-3.27
Net change in Cash	19.23
Free Cash Flow	54.35

Particulars	MAR 2022 (Values in Cr)
Net Income	17.98
Cash from Operations	19.76
Cash from Investing	-7.30
Cash from Financing	-8.24
Net change in Cash	-0.12
Free Cash Flow	23.03

Particulars	MAR 2021 (Values in Cr)
Net Income	14.13
Cash from Operations	19.23
Cash from Investing	-2.82
Cash from Financing	-5.93
Net change in Cash	7.77
Free Cash Flow	19.92

Particulars	MAR 2020 (Values in Cr)
Net Income	13.81
Cash from Operations	21.16
Cash from Investing	-3.01
Cash from Financing	-11.34
Net change in Cash	3.09
Free Cash Flow	24.17

Particulars	MAR 2024 (Values in Cr)
Net Income	36.91
Cash from Operations	23.51
Cash from Investing	-4.52
Cash from Financing	-10.60
Net change in Cash	-1.11
Free Cash Flow	27.74

Particulars	MAR 2023 (Values in Cr)
Net Income	38.61
Cash from Operations	44.91
Cash from Investing	-11.35
Cash from Financing	-3.27
Net change in Cash	21.28
Free Cash Flow	56.39

Particulars	MAR 2022 (Values in Cr)
Net Income	17.80
Cash from Operations	17.52
Cash from Investing	-7.30
Cash from Financing	-8.24
Net change in Cash	-2.37
Free Cash Flow	20.78

Particulars	MAR 2021 (Values in Cr)
Net Income	13.97
Cash from Operations	20.90
Cash from Investing	-2.82
Cash from Financing	-5.93
Net change in Cash	9.44
Free Cash Flow	21.58

Particulars	MAR 2020 (Values in Cr)
Net Income	13.50
Cash from Operations	18.12
Cash from Investing	-3.01
Cash from Financing	-11.34
Net change in Cash	0.06
Free Cash Flow	21.14

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
RELIANCE INFRASTRUCTU LTD	250.20	0.00	0.78	9911.20	143.70 / 350.90
ITD CEMENTATION INDIA LTD	525.25	25.87	5.53	9023.14	320.05 / 694.45
HINDUSTAN CONSTRUCTION CO	25.20	0.00	5.30	4584.85	21.37 / 57.46
ION EXCHANGE (INDIA) LTD	482.40	32.57	6.45	7075.20	401.05 / 767.00

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
RELIANCE INFRASTRUCTU LTD	250.20	0.00	1.21	9911.20	143.70 / 350.90
ITD CEMENTATION INDIA LTD	525.25	25.87	5.53	9023.14	320.05 / 694.45
HINDUSTAN CONSTRUCTION CO	25.20	0.00	2.36	4584.85	21.37 / 57.46
INDIAN HUME PIPE CO. LTD.	388.35	19.97	2.36	2045.90	250.60 / 613.15

Technicals

EMA & SMA
Resistance and Support
Price Change Analysis

Bullish Moving Averages -

Bearish Moving Averages -

5 Days 148.80
26 Days 141.00
10 Days 146.90
50 Days 146.60
12 Days 145.60
100 Days 164.60
20 Days 141.90
200 Days 190.90

150.43
PIVOT

First Resistance	153.85
Second Resistance	157.33
Third Resistance	160.75

First Support	146.95
Second Support	143.53
Third Support	140.05

RSI	57.24
MACD	4.59
Commodity Channel Index (CCI)	64.45

ADX	25.68
Williams % R	-31.63

Mold-tek Technologies Ltd Future

Future: Price

25 May

0 100 200 300 400 500 600

Discount/Premium

25 May

0 1 2 3 4 5 6 7

Active Calls

25 May

0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul

0 500 1000 1500 2000 2500

Stock Holding

View Live Stock Screeners

Holding

Public

50.6 Promoter Holdings

49.04 FII

0.02 DII

0.33 Promoter Shares(Pledge Percentage)

0.0

Name	Category	Shares	Shares%
Mold Tek Packaging Limited	Shareholding of Promoter and Promoter Group	2117165.0	7.41
Sudharani Janumahanti	Shareholding of Promoter and Promoter Group	1901513.0	6.66
Lakshmana Rao Janumahanti	Shareholding of Promoter and Promoter Group	1316023.0	4.61
Navya Mythri Janumahanti	Shareholding of Promoter and Promoter Group	1307940.0	4.58
A Durga Sundeep	Shareholding of Promoter and Promoter Group	1003144.0	3.51
Lakshmi Mythri Adivishnu	Shareholding of Promoter and Promoter Group	896067.0	3.14
Janumahanti Sathya Sravya	Shareholding of Promoter and Promoter Group	866200.0	3.03
Ranapratap Janumahanti	Shareholding of Promoter and Promoter Group	861200.0	3.01
Subramanyam Adivishnu	Shareholding of Promoter and Promoter Group	765090.0	2.68
Shubhi Consultancy Services Llp	Public Shareholding	648500.0	2.27
Nandivada Padmavathi	Shareholding of Promoter and Promoter Group	532500.0	1.86
Sarada Janumahanti	Shareholding of Promoter and Promoter Group	511919.0	1.79
Seshukumari Adivishnu	Shareholding of Promoter and Promoter Group	456176.0	1.6
Venkata Appa Rao Kota Giri	Public Shareholding	379144.0	1.33
Nandiwada Vara Prasad	Shareholding of Promoter and Promoter Group	238495.0	0.83
Venkateswara Rao Pattabhi	Shareholding of Promoter and Promoter Group	227230.0	0.8
Bhujanga Rao Janumahanti	Shareholding of Promoter and Promoter Group	203054.0	0.71
Virat Laxman Janumahanti	Shareholding of Promoter and Promoter Group	200000.0	0.7
Golukonda Satyavati	Shareholding of Promoter and Promoter Group	186993.0	0.65
Sai Lakshmi Pattabhi	Shareholding of Promoter and Promoter Group	134500.0	0.47
Prasanna Kumar Golkonda	Shareholding of Promoter and Promoter Group	93812.0	0.33
Santosh Narayan Vamsi Prasad Posemsetty	Shareholding of Promoter and Promoter Group	75500.0	0.26
Kavya Sarraju	Shareholding of Promoter and Promoter Group	50000.0	0.18
Vihaan Laxman Posemsetty	Shareholding of Promoter and Promoter Group	50000.0	0.18
Swetha Mythri Janumahanti	Shareholding of Promoter and Promoter Group	12450.0	0.04
P Apparao	Shareholding of Promoter and Promoter Group	1209.0	0.0

Mold-tek Technologies Ltd

Ex-Date	Dividend Amt.	Dividend Type	Record Date	Instrument Type
2023-09-18	1.4	Final	2023-09-20	Equity shares	2023-04-21	2.0	Interim	2023-04-21	Equity shares	2022-09-22	0.3	Final	2022-09-24	Equity shares	2022-03-23	1.7	Interim	2022-03-24	Equity shares	2021-09-22	0.8	Final	2021-09-24	Equity shares	2021-03-16	0.6	Interim	2021-03-17	Equity shares	2020-03-19	1.5	Interim	2020-03-21	Equity shares	2019-09-20	0.6	Final	2019-09-24	Equity shares	2019-04-23	0.8	Interim	2019-04-24	Equity shares	2018-09-19	0.4	Final	2018-09-23	Equity shares	2018-05-21	0.3	Interim	2018-05-22	Equity shares	2017-09-14	0.3	Final	2017-09-16	Equity shares	2017-04-27	0.3	Interim	2017-04-28	Equity shares	2016-09-09	0.2	Final	2016-09-13	Equity shares	2016-03-18	0.4	Interim	2016-03-21	Equity shares	2016-03-18	0.2	Special	2016-03-21	Equity shares	2015-09-18	1.5	Final	2015-09-22	Equity shares	2015-04-21	2.0	Interim	2015-04-22	Equity shares	2014-09-24	0.8	Final	2014-09-26	Equity shares	2014-02-14	1.0	Interim	2014-02-17	Equity shares	2013-09-16	1.2	Final	2013-09-18	Equity shares	2012-09-13	1.0	Final	2012-09-17	Equity shares	2011-08-12	1.5	Final	2011-08-17	Equity shares	2010-09-23	1.5	Final	2010-09-27	Equity shares	2009-09-24	2.0	Final	2009-09-28	Equity shares	2008-09-18	2.0	Final	2008-09-25	Equity shares	2007-09-20	2.0	Final	2007-09-22	Equity shares	2006-09-19	0.0	Final	2006-09-21	Equity shares

Learn More About Stocks

Dr Reddy’s Denies Workforce Reduction Claims Amid Cost-Cut Rumours

Dr Reddy’s Laboratories rejects claims of reducing workforce costs by 25%, asserting no such plans or internal directives.

15 Apr, 2025 | 3 Min. read

Glenmark, Sun Pharma, Zydus Recall Drugs in US over Compliance Issues

Glenmark, Sun Pharma, and Zydus recall multiple drug batches in the US following manufacturing deviations and contamination concerns as per USFDA enforcement reports.

15 Apr, 2025 | 3 Min. read

HAL Denies Selecting PwC for R&D Benchmarking Amid Ongoing Bids

HAL clarifies no consultancy firm has been finalised for R&D benchmarking amid social media buzz about PwC. Selection process still ongoing via GeM portal.

15 Apr, 2025 | 3 Min. read

Aurobindo Pharma Gets USFDA Nod for Generic Xarelto 2.5mg Tablets

Aurobindo Pharma receives USFDA approval to launch generic Xarelto 2.5mg in Q1 FY26, targeting $447 million US market; higher strengths also gain tentative nod.

15 Apr, 2025 | 3 Min. read

IndiGo Becomes World’s Most Valuable Airline With $23.4 Billion Market Cap

IndiGo surpasses global peers to become the most valuable airline by market cap at $23.4 billion, pushing InterGlobe Aviation share price to record highs in 2025.

11 Apr, 2025 | 3 Min. read

SRF Ltd. Commissions New Agrochemical Unit in Dahej Worth Rs.239 Crore

SRF Ltd. starts new agrochemical facility in Dahej, Gujarat with Rs.239 crore investment. Phase 1 operational, full commissioning set for April 2025.

11 Apr, 2025 | 3 Min. read

Tata Motors’ JLR India Achieves Record Sales in FY25 at 6,183 Units

JLR India posts record-breaking FY25 retail sales of 6,183 units, up 40%. Defender leads growth, boosting Tata Motors share price sentiment.

11 Apr, 2025 | 4 Min. read

Biocon Gets USFDA Approval for Jobevne, Expands Oncology Portfolio

Biocon Biologics receives USFDA nod for cancer drug Jobevne, a bevacizumab biosimilar. Oncology portfolio in US grows, boosting Biocon Ltd. share price outlook.

11 Apr, 2025 | 3 Min. read